Exploring the effects of Esketamine on dissociative states in depression
Phenomenological Explorations of the Esketamine-Induced Transient Dissociative State
This study is testing how Esketamine affects feelings of disconnection in people with hard-to-treat depression to see how it impacts their overall treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 15 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer Academic / other |
| Locations | 1 site (Toulon, Var) |
| Trial ID | NCT06133309 on ClinicalTrials.gov |
What this trial studies
This study investigates the transient dissociative state induced by Esketamine, a treatment for resistant depressive disorders. Patients receiving Esketamine at the Psychiatry Department of Hôpital Sainte Musse will be selected based on specific inclusion criteria and will participate in an Experiential Phenomenological Interview. The study aims to understand the cognitive and emotional disruptions experienced during this dissociative state and how it affects the overall treatment outcome. Participants will provide oral consent and complete a questionnaire during a follow-up consultation.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 who have been treated with Esketamine for depression and experienced a transient dissociative state.
Not a fit: Patients with major anxiety or panic attacks during the dissociative state or those under judicial protection will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of dissociative effects during Esketamine treatment, potentially improving therapeutic strategies for patients with depression.
How similar studies have performed: While few studies have explored this phenomenon in the context of Esketamine, related research on ketamine has shown promising insights into dissociative experiences.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient followed in the Psychiatry Department of Hôpital Sainte Musse, with depressive state characterized by the DSM-V criteria and treated with Esketamine between 2 days and 3 months prior to the study; * Patient over the age of 18; * Patient presented transient dissociative state during Esketamine treatment; * Patient able to express his/her consent prior to participation in the study; * Patient who understands and speaks French. Exclusion Criteria: * Patient with major anxiety and panic attack during an Esketamine-induced dissociative state, regardless of Esketamine effect; * Patient under judicial protection (guardianship, curatorship...) or safeguard of justice; * Pregnant, parturient or breast-feeding women; * Any other reason that, in the opinion of the investigator, would interfere with the evaluation of the study objectives.
Where this trial is running
Toulon, Var
- Centre Hospitalier Intercommunal Toulon La Seyne sur Mer — Toulon, Var, France (Recruiting)
Study contacts
- Study coordinator: Sophie LAFOND
- Email: sophie.lafond@ch-toulon.fr
- Phone: 0483772062
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.